John Mascarenhas

Icahn School Of Medicine At Mount Sinai

$6,187,399

Attributed

$6,187,399

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY2018–25

$2M$1.5M$1M$500K$0

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$5,687,768 · 2

CDC$499,631 · 1

By mechanism

P01$5,687,768 · 2

U01$499,631 · 1

Top collaborators

No co-investigators on record.

Most similar at Icahn School Of Medicine At Mount Sinai

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Malignant - Descriptor”

Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
Martha Hering · Westat, Inc.$57,098,843

Research focus

Malignant - DescriptorIn VivoFocus GroupsImproved OutcomeInfrastructureIn VitroEvolutionExperimental StudyImpairmentHematopoietic Stem CellsBloodCessation Of LifeBone MarrowInvestigationBiological MarkersDisease Natural HistoryClinical TrialsClinical Trials Cooperative GroupAggressive Clinical CourseFundingDisease ProgressionHematopoiesisDesignMember